Generic name: Loperamide
Brand name: Lormide
Dosage: 2mg capsule
Formulation: Each capsule contains loperamide hydrochloride 2mg
Loperamide (Lormide) directly affects the nerve endings and/or intramural ganglia of the intestinal wall. It decreases the circular and longitudinal activity of the muscles in the intestinal wall. It also enhances contractions of the intestinal circular musculature increasing segmentation and retarding forward motion through the intestine.
Loperamide (Lormide) prolongs the transit time of intestinal contents and reduces fecal volume, increase fecal viscosity, bulk density and lessens loss of fluid and electrolytes.
Absorption. Peak plasma concentration of loperamide occurs about 2.5 or 4-5 hours following administration. Peak plasma concentration of Loperamide (Lormide) metabolites are reached 8 hours after oral administration.
Distribution. It is not known if Loperamide (Lormide) crosses the placenta or is distributed into milk.
Elimination. Elimination half-life of Loperamide (Lormide) in healthy adults is 10.8 hours.
For the symptomatic control of acute and chronic diarrhea. Can be used in patients with ileostomy to reduce the number and volume of stools and to harden their consistency.
The first line of treatment for diarrhea with dehydration is oral replacement fluid.
Acute diarrhea: Two capsules initially followed by 1 capsule after each unformed stool. Dosage should not exceed 16mg/day or 8 capsules/day. The usual daily dose is 6 to 8 mg/day or 3 to 4 capsules/day.
Chronic diarrhea. Two capsules initially, then adjust dose until1-2 solid stools/day are obtained. Dosage should not exceed 8 capsules/day.
Discontinue when constipation, abdominal distention or ileus develop.
Should not be used in patients with acute ulcerative colitis or pseudomembraneous colitis associated with broad-spectrum antibiotics.
Should not be used in acute dysentery which is characterized by high fever and blood in stools
Patients with hepatic dysfunction should be monitored closely for signs and symptoms of CNS toxicity during loperamide therapy, since the first-pass metabolism may be decreased in these patients. Patients should be advised to consult their physician if diarrhea persists or if no clinical improvement is observed within 48 hours.
Patients receiving anti-infective or with history of liver diseases should consult their physician before taking loperamide.
Contraindicated in patients with known hypersensitivity to loperamide and in whom constipation must be avoided.
Lopermide (Lormide) is not recommended in children below 4 years of age.
Pregnancy and Lactation:
There are no clinical studies on the safety of Loperamide (Lormide) in pregnant and lactating women. Loperamide (Lormide) should be used only if clearly needed.
Hypersensitivity reactions, constipation, nausea and vomiting, tiredness, drowsiness or dizziness and dry mouth (which are difficult to distinguish from symptoms due to diarrhea)
Symptoms may be manifested by paralytic ileus and CND depression.
Treatment: In loperamide (Lormide) overdosage, gastric lavage is recommended. Naloxone may be administered if CNS depression occurs. Because the duration of action of Loperamide (Lormide) is longer than that of naloxone, repeat treatment with naloxone may be indicated. Vital signs should be monitored for recurrence of symptoms of Loperamide (Lormide) overdose for at least 24 hours after the last dose of naloxone.
Store at temperatures not exceeding 30 degrees Celsius.
Availability. Box of 100’s